Monday, November 16, 2026

Vivozon Pharmaceutical Places an Additional Order for 110,000 Vials of Non-Opioid Painkiller 'JOURNAVX'

Input
2026-11-16 09:28:22
Updated
2026-11-16 09:28:22
[Financial News] Vivozon Pharmaceutical's non-opioid painkiller JOURNAVX has seen its prescribing base and usage grow since its launch, prompting a move to expand supply. After establishing a prescribing base at major hospitals, its sales reach expanded to regional medical institutions, leading to an additional order.
Vivozon Pharmaceutical said on the 16th that it had placed an additional order for about 113,000 vials to meet rising sales of JOURNAVX. Since its domestic launch last October, prescriptions have increased, particularly at major hospitals, prompting the company to secure a stable supply.
JOURNAVX has passed pharmacy committee (DC) reviews at about 60 medical institutions with 300 or more beds. After major tertiary general hospitals such as Samsung Medical Center (SMC) and Severance Hospital, prescription code registration has also been completed at major national university hospitals, including Kyungpook National University Hospital (KNUH), Pusan National University Hospital and Chonnam National University Hospital.
The company is also securing new accounts at regional medical institutions with demand for post-surgical pain management, including orthopedics, neurosurgery and anesthesiology and pain medicine departments. As the expansion of prescribing to new sites at major hospitals and increased use at existing hospitals spread into the local market, the drug's sales base is growing.
Production is handled by China's Huiyu Pharmaceutical. JOURNAVX is Korea's 38th domestically developed novel drug, developed by Vivozon, and controls pain through a mechanism involving glycine transporter type 2 (GlyT2) inhibition and serotonin receptor 2A (5-HT2A) antagonism. It is used to manage moderate to severe post-surgical pain and is a non-opioid treatment that works differently from opioid analgesics.
A Vivozon Pharmaceutical representative said, "The number of hospitals prescribing it and the amount used have continued to increase since its launch," adding, "We will reliably meet demand in clinical settings while continuing to expand prescribing opportunities."

[email protected] Jung Sang-hee Reporter